InnoSlim is a stimulant-free body recomposition ingredient developed by Nuliv, the company behind the popular absorption enhancer AstraGin, the effective sleep-supporting Zylaria, and the ATP-enhancing Senactiv. InnoSlim is a unique blend of Panax notoginseng and Astragalus membranaceus, and early research highlighted a number of attractive benefits for those seeking to lose weight and improve body composition.
The first human clinical study on InnoSlim was recently published, where a number of other notable health benefits were documented, particularly regarding cardiovascular health. The study involved 12 individuals over 20 years of age who took part in a 16-week randomized, double-blinded crossover trial. They all met the eligibility criteria of 100–125mg/dL fasting blood glucose levels, 5.8–6.4% HbA1C, and 200–249 mg/dL cholesterol.
The trial was broken down into a six-week first phase, a four-week washout period, then another six weeks for a second phase. During the six-week phases, participants would consume either a placebo or 250mg of Nuliv’s InnoSlim.
At the end of the study, researchers found six weeks of InnoSlim significantly reduced blood glucose levels (10.1%), triglycerides (31.06%), and low-density lipoprotein-cholesterol (19.96%) compared to placebo. Researchers also noted impressive improvements in HDL-Cholesterol (11.78%), AMPK (12.72%), and adiponectin (22.07%), a hormone secreted by fat cells that activates AMPK which subsequently inhibits gluconeogenesis and maintains the balance of blood glucose and lipids.
Based on those findings, the team of researchers concluded that Nuliv’s InnoSlim can be effective for reducing high blood sugar (hyperglycemia) and cholesterol (hypercholesterolemia), alongside all of its many weight loss benefits. Many supplements on the market are now relying on InnoSlim, and for good reason, including Glaxon’s stimulant-free Thermal, Alpha Lion’s Cravings Killer, and Apollon’s stimulant-heavy Chaos.
